Table 4.

Effect of LN18178 supplementation on hand-grip strength and PSS-10 score of the participants through the course of the trial

Variable	Evaluation days	Placebo	LN18178-200	LN18178-400
Hand-Grip Strength (Kg)	Baseline	35.31 ± 11.28	35.52 ± 13.13	35.11 ± 13.16
	Day 7	36.59 ± 13.01	37.45 ± 12.24 (0.0349*; 0.8292#)	38.12 ±14.82 (0.0001*; 0.2627#)
	Day 14	37.12 ± 11.73	39.26 ±12.58 (0.0003*; 0.4544#)	40.96 ±16.14 (0.0003*; 0.0341#)
	Day 28	37.00 ± 13.62	39.94 ± 11.43 (0.0001*; 0.2829#)	42.75 ± 16.18 (<0.0001*; 0.0031#)
	Day 56	36.65 ± 11.19	42.25 ± 12.37 (<0.0001*; 0.0056#)	43.76 ± 15.34 (<0.0001*; <0.0001#)
Perceived Stress Scale (PSS-10) score	Baseline	19.63 ± 5.096	20.14 ± 5.067	19.60 ± 5.363
	Day 7	19.45 ± 5.060	19.92 ± 5.325 (0.0882*; 0.9854#)	19.38 ± 5.348 (0.1068*; 0.9752#)
	Day 14	18.97 ± 4.594	18.68± 4.410 (0.0002*; 0.1851#)	17.85 ± 4.742 (0.0001*; 0.0172#)
	Day 28	18.89 ± 4.637	17.38 ± 4.412 (0.0001*; 0.0031#)	16.25 ±4.749 (0.0001*; <0.0001#)
	Day 56	18.92 ± 5.18	16.14 ± 4.263 (<0.0001*; 0.0003#)	14.50 ± 5.149 (<0.0001*; <0.0001#)

Data present as mean ± SD. Placebo (n=38), LN18178-200 (n=37), and LN18178-400 (n=40). In parentheses, * and # indicate P-values in intragroup comparison (vs. baseline) using student t-test and in intergroup comparison (vs. placebo) analyzed using ANCOVA, respectively; NS, not significant.